Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
$KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
$KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
$KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
$KORS William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-michael-kors-despite-strong-quarterly-earnings/
William Blair Reaffirms Market Perform On Michael Kors Despite Strong Quarterly Earnings http://bit.ly/1pALMlM
We Expect ISIS Shares To Outperform The Market, Says Cowen http://www.smarteranalyst.com/2014/08/05/we-expect-isis-shares-to-outperform-the-market-says-cowen/
William Blair Maintains Outperform On Cardinal Health Following Fiscal Fourth Quarter Results http://www.smarteranalyst.com/2014/08/05/william-blair-maintains-outperform-on-cardinal-health-following-fiscal-fourth-quarter-results/
$AMGN William Blair Reaffirms Market Perform On Amgen Following Positive Phase III ASPIRE Results http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-amgen-following-positive-phase-iii-aspire-results/
$AMGN William Blair Reaffirms Market Perform On Amgen Following Positive Phase III ASPIRE Results http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-market-perform-on-amgen-following-positive-phase-iii-aspire-results/
$THLD Threshold Remains Undervalued, Says William Blair http://www.smarteranalyst.com/2014/08/04/threshold-remains-undervalued-says-william-blair/
$LCI Lannett: Oxycodone Hydrochloride Approval Incremental Plus, Says Wedbush http://www.smarteranalyst.com/2014/08/04/lannett-oxycodone-hydrochloride-approval-incremental-plus-says-wedbush/
$LCI Lannett: Oxycodone Hydrochloride Approval Incremental Plus, Says Wedbush http://www.smarteranalyst.com/2014/08/04/lannett-oxycodone-hydrochloride-approval-incremental-plus-says-wedbush/
We Think NPSP Could Surprise To The Upside, Says Wedbush http://www.smarteranalyst.com/2014/08/04/we-think-npsp-could-surprise-to-the-upside-says-wedbush/
$DRTX Roth Capital Affirms Buy On Durata Therapeutics Following License Agreement With Angelini http://bit.ly/1qUvqbc
$MNTA Maxim Maintains Buy On Momenta As The Battle On Copaxone Continues http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-momenta-as-the-battle-on-copaxone-continues/
$TKMR Maxim Maintains Buy On Tekmira Following Ebola Report; Keeps $23 PT http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-tekmira-following-ebola-report-keeps-23-pt/
$TKMR Maxim Maintains Buy On Tekmira Following Ebola Report; Keeps $23 PT http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-tekmira-following-ebola-report-keeps-23-pt/
$TKMR Maxim Maintains Buy On Tekmira Following Ebola Report; Keeps $23 PT http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-tekmira-following-ebola-report-keeps-23-pt/
$TKMR Maxim Maintains Buy On Tekmira Following Ebola Report; Keeps $23 PT http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-tekmira-following-ebola-report-keeps-23-pt/
Maxim Maintains Buy On Medivation As Xtandi Continues To Exceed Expectations http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-medivation-as-xtandi-continues-to-exceed-expectations/
$WWWW Recent Pullback Makes Web.com Valuation Interesting, Says Roth Capital http://www.smarteranalyst.com/2014/08/04/recent-pullback-makes-web-com-valuation-interesting-says-roth-capital/
Roth Capital Reiterates Buy On ANI Pharmaceuticals Following Vancocin Acquisition http://www.smarteranalyst.com/2014/08/04/roth-capital-reiterates-buy-on-ani-pharmaceuticals-following-vancocin-acquisition/
Roth Capital Reiterates Buy On ANI Pharmaceuticals Following Vancocin Acquisition http://www.smarteranalyst.com/2014/08/04/roth-capital-reiterates-buy-on-ani-pharmaceuticals-following-vancocin-acquisition/
Will Las Vegas Sands Loose Some Of Its Volatility And Get Into A Steady Growth? http://www.smarteranalyst.com/2014/08/04/will-las-vegas-sands-loose-some-of-its-volatility-and-get-into-a-steady-growth/
Axiom Maintains Bearish Expectaions On First Solar Ahead Of 2Q14 Results; Reduces PT To $28 http://www.smarteranalyst.com/2014/08/04/axiom-maintains-bearish-expectaions-on-first-solar-ahead-of-2q14-results-reduces-pt-to-28/
$TSLA Analysts Set Expectations On Tesla Motors Following 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/01/analysts-set-expectations-on-tesla-motors-following-2q14-earnings-results/
$CYTK Valuation Of Cytokinetics Shares Remain Attractive At These Levels, Says Roth Capital http://www.smarteranalyst.com/2014/08/01/cytokinetics-valuation-of-cytk-shares-remain-attractive-at-these-levels-says-roth-capital/
Valuation Of Cytokinetics Shares Remain Attractive At These Levels, Says Roth Capital http://www.smarteranalyst.com/2014/08/01/cytokinetics-valuation-of-cytk-shares-remain-attractive-at-these-levels-says-roth-capital/
Janney Reiterates Buy On Medivation Following Astellas’ Xtandi Sales Report; Sees $110 Fair Value http://www.smarteranalyst.com/2014/08/01/janney-reiterates-buy-on-medivation-following-astellas-xtandi-sales-report-sees-110-fair-value/
$MDVN Janney Reiterates Buy On Medivation Following Astellas’ Xtandi Sales Report; Sees $110 Fair Value http://www.smarteranalyst.com/2014/08/01/janney-reiterates-buy-on-medivation-following-astellas-xtandi-sales-report-sees-110-fair-value/
$EDAP We Believe A Positive FDA Decision Is Now Unlikely, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/01/edap-we-believe-a-positive-fda-decision-is-now-unlikely-says-h-c-wainwright/
Seattle Genetics: Recent Macro Weakness Has Created A Buying Opportunity, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/01/seattle-genetics-recent-macro-weakness-has-created-a-buying-opportunity-says-h-c-wainwright/
$SGEN Seattle Genetics: Recent Macro Weakness Has Created A Buying Opportunity, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/01/seattle-genetics-recent-macro-weakness-has-created-a-buying-opportunity-says-h-c-wainwright/
Roth Capital Reiterates Buy On Pixelworks On Positive Long-Term Outlook; Raises PT To $12 http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-pixelworks-on-positive-long-term-outlookl-raises-pt-to-12/
Roth Capital Reiterates Buy On Hecla Mining Following 2Q14 Financial Results http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-hecla-mining-following-2q14-financial-results/
Roth Capital Reiterates Buy On Hecla Mining Following 2Q14 Financial Results http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-hecla-mining-following-2q14-financial-results/
$SRPT Roth Capital Reiterates Buy On Sarepta Following Appointment Of New Interim Chairman http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-sarepta-following-appointment-of-new-interim-chairman/
$SRPT Roth Capital Reiterates Buy On Sarepta Following Appointment Of New Interim Chairman http://www.smarteranalyst.com/2014/08/01/roth-capital-reiterates-buy-on-sarepta-following-appointment-of-new-interim-chairman/